Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422208 | 0.77 | MKNK1 (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL183189 | 0.72 | KDM4E (0.36) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL11611665 | 0.63 | IP6K1 (0.44) | ALDH1A1 | |
| SCHEMBL30677255 | 0.63 | KDM4E (0.39) | KDM4EALDH1A1GAA | |
| SCHEMBL183274 | 0.63 | KDM4E (0.39) | KDM4EALDH1A1GAA | |
| SCHEMBL15987788 | 0.63 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL15322620 | 0.62 | IP6K1 (0.43) | ALDH1A1 | |
| SCHEMBL680853 | 0.61 | NPC1 (0.45) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4924089 | 0.61 | KDM4E (0.48) | KDM4EHSD17B10 | |
| SCHEMBL7311364 | 0.61 | ALDH1A1 (0.47) | KDM4EALDH1A1GLAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2013-05-02 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEURO SEARCH A/S/ (DK) | 2010-06-17 | — | — | US | disclosed |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100105705-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2144911-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| EP-2142546-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-2142545-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-2142547-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-2132208-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116910-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116911-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116914-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KDM4E 917/4885ALDH1A1 3364/4885GLA 4535/4885 |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KDM4E 917/4885ALDH1A1 3364/4885GLA 4535/4885 |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KDM4E 917/4885ALDH1A1 3364/4885GLA 4535/4885 |
| US-20100105705-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KDM4E 917/4885ALDH1A1 3364/4885GLA 4535/4885 |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KDM4E 917/4885ALDH1A1 3364/4885GLA 4535/4885 |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KDM4E 917/4885ALDH1A1 3364/4885GLA 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.